01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
06:11 , Aug 10, 2018 |  BC Week In Review  |  Company News

BlackThorn licenses Yale's neuroimaging tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
23:38 , Aug 6, 2018 |  BC Extra  |  Company News

BlackThorn licenses Yale's neuroimaging drug discovery tech

Neurobehavioral disorder company BlackThorn Therapeutics Inc. (San Francisco, Calif.) exclusively licensed neuroimaging technology from Yale University School of Medicine designed to link gene expression patterns with behavioral circuits in the brain. Yale has dubbed the...
17:49 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Cara raises $85.5M follow-on

Cara Therapeutics Inc. (NASDAQ:CARA) raised $85.5 million on July 18 through the sale of 4.5 million shares at $19 in a follow-on underwritten by Jefferies, BofA Merrill Lynch, Piper Jaffray, Stifel, Canaccord Genuity, Needham, H.C....
18:20 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA advisory committee votes against approval of Pain's Remoxy

At a June 26 joint meeting, FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 14-3 against approval of Remoxy ER oxycodone extended release (PF-00345439) from Pain...
14:53 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Cara's IV analgesic meets in Phase III for postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 trial to treat postoperative pain in patients undergoing abdominal surgery. On the primary endpoint, the 1...
20:24 , Jun 27, 2018 |  BC Extra  |  Clinical News

Cara gains after analgesic readout

Cara Therapeutics Inc. (NASDAQ:CARA) added $1.62 (10%) to $18.06 Wednesday after IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 study to treat postoperative pain in patients undergoing abdominal surgery....
19:19 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...
18:33 , May 25, 2018 |  BC Week In Review  |  Company News

Vifor Fresenius to commercialize Cara’s Korsuva in international markets

Cara Therapeutics Inc. (NASDAQ:CARA) granted Vifor Fresenius Medical Care Renal Pharma Ltd. rights to commercialize Korsuva difelikefalin (IV CR845) to treat chronic kidney disease-associated pruritus in dialysis patients. Vifor Fresenius acquired worldwide rights, excluding the...
21:30 , May 23, 2018 |  BC Extra  |  Company News

Vifor Fresenius to commercialize Cara’s Korsuva in international markets

Cara Therapeutics Inc. (NASDAQ:CARA) gained $4.96 (43%) to $16.56 on Wednesday after Vifor Fresenius Medical Care Renal Pharma Ltd. acquired rights to commercialize Korsuva difelikefalin (IV CR845) to treat chronic kidney disease-associated pruritus in dialysis...